FRESH-PEF73865-en
SFCE national cohort on SARS-CoV-2 (COVID-19) infections in paediatric oncology-haematology
PEDONCOVID
| Name | Country code |
|---|---|
| France | fr |
['Clinical data','Biological data']
Individuals
| Topic | Vocabulary |
|---|---|
| Paediatrics | health theme |
| Neoplasms | cim-11 |
| COVID-19 | cim-11 |
{"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Infant, Newborn (birth to 28 days)","concept":{"vocab":"MeSH","vocabURI":"D007231"}},{"value":"Infant (28 days to 2 years)","concept":{"vocab":"MeSH","vocabURI":"D007223"}},{"value":"Child, Preschool (2 to 5 years)","concept":{"vocab":"MeSH","vocabURI":"D002675"}},{"value":"Child (6 to 12 years)","concept":{"vocab":"MeSH","vocabURI":"D002648"}},{"value":"Adolescent (13 to 18 years)","concept":{"vocab":"MeSH","vocabURI":"D000293"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"Children and legal representatives, or adult patients having received information on the study AND - Patient followed up in a paediatric oncology-haematology department or young adult and adolescent unit at an SFCE centre for cancer or a benign tumour treated with chemotherapy, radiotherapy or targeted therapy, with a cancer treatment either ongoing or completed within the past 6 months, or a history of allogeneic haematopoietic stem cell transplantation with immunosuppressant therapy ongoing or discontinued within the past 6 months, or a history of CAR-T cell therapy AND - Diagnosis of SARS-CoV-2 infection confirmed by PCR or positive IgM serology OR - Clinical and radiological diagnosis characteristic of SARS-CoV-2 infection without confirmation of infection by PCR or positive IgM serology with: o Presence of at least 2 of the following signs in the event of contact with a subject currently presenting SARS-CoV-2 positive infection, or 3 of the following signs in the absence of contact: fever, cough, dysgeusia, dysosmia, myalgia, chest pain, dyspnoea, signs of respiratory distress, rhinorrhoea or nasopharyngeal congestion, diarrhoea, headaches, recent onset or exacerbation of asthenia and rash. AND o One or more radiological abnormalities observed on chest CT scan compatible with a diagnosis of COVID-19: peripheral and/or subpleural and/or bilateral ground-glass opacities, intralobular thickening with a crazy-paving appearance, linear condensations with or without peripheral halo (reverse halo sign).","clusion_E":""}
| Name |
|---|
| Jérémie;ROUGER-GAUDICHON |
| Name | Role |
|---|---|
| CENTRE HOSPITALIER UNIVERSITAIRE DE CAEN NORMANDIE (CHU) | sponsor |
| Agency name |
|---|
| CPP |
['Through organizations (health services or institutions, schools, businesses, etc.)']
['{"concept":{"vocabURI":"Other","vocab":"CESSDA"},"value":"Other"}']
Observational Study
{"value":"To be defined","extLink":[]}